Equities

Oncolys Biopharma Inc

4588:TYO

Oncolys Biopharma Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)582.00
  • Today's Change11.00 / 1.93%
  • Shares traded278.30k
  • 1 Year change-15.04%
  • Beta1.1933
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,5331,7113,455
Total Receivables, Net102318377
Total Inventory5.342412
Prepaid expenses316554355
Other current assets, total0.010.510.02
Total current assets1,9562,6094,198
Property, plant & equipment, net000
Goodwill, net------
Intangibles, net----0
Long term investments212121
Note receivable - long term43--35
Other long term assets212121
Total assets2,0412,6514,292
LIABILITIES
Accounts payable------
Accrued expenses191717
Notes payable/short-term debt505050
Current portion long-term debt/capital leases85181192
Other current liabilities, total22473172
Total current liabilities379322430
Total long term debt180162262
Total debt315394503
Deferred income tax------
Minority interest------
Other liabilities, total8.147.755.76
Total liabilities567492698
SHAREHOLDERS EQUITY
Common stock3,6233,0009,040
Additional paid-in capital1,2105869,064
Retained earnings (accumulated deficit)(3359)(1427)(14509)
Treasury stock - common(0.14)(0.14)(0.11)
Unrealized gain (loss)------
Other equity, total0--0.00
Total equity1,4742,1593,594
Total liabilities & shareholders' equity2,0412,6514,292
Total common shares outstanding201717
Treasury shares - common primary issue0.090.080.07
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.